Having trouble accessing articles? Reset your cache.

Product Development
NGM pops on additional Phase II NASH data for aldafermin

Positive histology data helped NGM snap a losing streak for NASH therapies and lifted the biotech’s stock on a day where the sector and broader markets saw mostly red.

Sanofi to launch spinout that could compete with Asia-sourced APIs

In a move that could help decrease industry reliance on APIs from Asia, Sanofi revealed plans to spin off its API business, which will be headquartered in France.

Karius looks to $165M B round to spur growth of diagnostic business

Karius has raised $165 million in a series B to grow its customer base and advance its DNA-based blood test technology.

SoftBank Vision Fund 2 led Karius ...

Feb. 24 Financial Quick Takes: Bio-Thera shines in first days on STAR; plus ImmuneOnco, GenCells, Twist and Axovant

Fast start for Bio-Thera on Shanghai’s STAR board
Bio-Thera Solutions Ltd. (Shanghai:688177) jumped RMB27.44 (84%) to RMB60.20 in its first day of trading ...

BioCentury ISSN 1097-7201